Bristol-Myers Squibb Co. reported Phase II results in psoriasis for BMS-986165, a selective inhibitor of tyrosine kinase 2 (TYK2), that show what the company's TYK2 program development lead John Throup described as "biologic-like efficacy, but with a very safe profile."
The data published in the New England Journal of Medicine and presented at the European Academy of Dermatology and Venerology (EADV) Congress in Paris on Sept. 12 may position BMS-986165 to compete with Janus kinase (JAK) inhibitors, a related drug class that's shown efficacy in psoriasis, psoriatic arthritis and inflammatory bowel disease (IBD), but with safety risks that the Bristol-Myers drug may avoid
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?